Pfizer Inc. (NYSE:PFE) Shares Sold by PSI Advisors LLC

PSI Advisors LLC trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 1.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 27,438 shares of the biopharmaceutical company’s stock after selling 397 shares during the period. PSI Advisors LLC’s holdings in Pfizer were worth $794,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the business. Global Assets Advisory LLC purchased a new position in Pfizer during the first quarter worth $725,000. Atlas Capital Advisors LLC boosted its stake in shares of Pfizer by 54.4% during the first quarter. Atlas Capital Advisors LLC now owns 1,702 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 600 shares during the last quarter. Sovereign Financial Group Inc. increased its position in Pfizer by 12.2% during the 1st quarter. Sovereign Financial Group Inc. now owns 16,929 shares of the biopharmaceutical company’s stock worth $470,000 after purchasing an additional 1,837 shares in the last quarter. Wealthcare Advisory Partners LLC lifted its holdings in Pfizer by 149.7% in the 1st quarter. Wealthcare Advisory Partners LLC now owns 129,868 shares of the biopharmaceutical company’s stock valued at $3,604,000 after purchasing an additional 77,868 shares in the last quarter. Finally, Edge Wealth Management LLC lifted its holdings in Pfizer by 2.0% in the 1st quarter. Edge Wealth Management LLC now owns 260,180 shares of the biopharmaceutical company’s stock valued at $7,220,000 after purchasing an additional 5,121 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. UBS Group boosted their price target on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Wells Fargo & Company raised their price objective on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Sanford C. Bernstein initiated coverage on Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Wednesday. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $33.91.

Pfizer Price Performance

Shares of Pfizer stock opened at $28.84 on Thursday. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $31.54. The stock has a market capitalization of $163.42 billion, a P/E ratio of -481.00, a PEG ratio of 1.02 and a beta of 0.67. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The business’s fifty day moving average price is $29.07 and its 200 day moving average price is $28.48.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. The company had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.67 earnings per share. As a group, research analysts anticipate that Pfizer Inc. will post 2.66 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.83%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio is presently -2,800.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.